Stock News & Analysis

Curaleaf looks eager to buy Aurora Cannabis, and that's helped to drive its value up.

A nice boost won't change the two problems that retirees will likely face.

Firefly trades at a fraction of AST's valuation multiple, but both burn cash at scale, here's which bet suits your risk appetite.

Every Rule Breaker investor eventually has to ask whether great leadership can outlive the people who built a company.

The stock has been hit hard over the past month.

Cintia Scovine Barcelos De Souza bought shares at $17.98 each on, boosting her direct holdings to 275,197 shares and signaling insider confidence.

The optical laser leader fell hard, along with the entire AI infrastructure sector, following cautionary remarks from a key sector CEO.

This decision could make a small but meaningful difference to your benefits.

Eos Energy's 631% revenue growth contrasts sharply with mounting losses and legal headwinds, while Plug Power faces DOE loan uncertainty and billion-dollar annual losses.

These four ETFs are top buys in any market.

Juliano Ribeiro Marcilio's acquisition expands his direct stake by 23%, signaling confidence in the Brazilian bank despite modest recent stock performance.

NEAR Protocol’s weekend rally had help from buybacks, a supply cut proposal, and some unlucky short sellers.

Nvidia and AMD traded closely for a long time, but that's no longer the case.

Going against the grain and buying stocks that are down big can involve risks, but it also may lead to terrific returns later on.

ASML is set to report Q3 earnings. Here's what to expect.

The social media company unveiled its Muse Wonder AI model.

The 10-year Treasury yield just hit 5.2%, dwarfing Costco's dividend. Here's why the warehouse retailer still looks like the better long-term buy.

ASML supplies the lithography systems chipmakers use and relies on four customers for about 61% of its sales, while TSMC manufactures chips for 534 customers and carries the risk of production concentrated in Taiwan.

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.

Stocks may be nearing risky territory, but history says there's a silver lining.